Aliases:This biomarker is also known as:
- mitochondrial RNase P subunit 2,
- 3-hydroxy-2-methylbutyryl-CoA dehydrogenase,
- short chain L-3-hydroxyacyl-CoA dehydrogenase type 2,
- Mitochondrial RNase P protein 2,
- 3-hydroxyacyl-CoA dehydrogenase type-2,
- 17-beta-hydroxysteroid dehydrogenase 10,
- 3-hydroxyacyl-CoA dehydrogenase type II,
- 17-beta-HSD 10,
- Mitochondrial ribonuclease P protein 2,
- short chain type dehydrogenase/reductase XH98G2,
- mitochondrial ribonuclease P protein 2,
- EC 220.127.116.11,EC 18.104.22.168,
- hydroxysteroid (17-beta) dehydrogenase 10,
- hydroxyacyl-Coenzyme A dehydrogenase, type II, hydroxyacyl-Coenzyme A dehydrogenase, type II,
- short chain dehydrogenase/reductase family 5C, member 1,
- Type II HADH,
- AB-binding alcohol dehydrogenase,
- amyloid-beta peptide binding alcohol dehydrogenase,
- Short-chain type dehydrogenase/reductase XH98G2,
- mental retardation, X-linked, syndromic 10,
- Endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
- endoplasmic reticulum-associated amyloid beta-peptide-binding protein,
HSD17B10, hydroxysteroid (17-beta) dehydrogenase 10, is a member of the short-chain dehydrogenase/reductase superfamily. HSD17B10 functions in mitochondrial tRNA maturation and catalyzes the oxidation of a wide variety of fatty acids, alcohols, and steroids. The protein is thought to play a role in the development of Alzheimer's disease. There are several alternatively spliced transcript variants, of which only two have been fully sequenced.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data is available.
HSD17B10 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.